Fibrinolysis shutdown (SD) is an independent risk factor for increased mortality in trauma. High levels of plasminogen activator inhibitor-1 (PAI-1) directly binding tissue plasminogen activator (t-PA) is a proposed mechanism for SD; however, patients with low PAI-1 levels present to the hospital with a rapid TEG (r-TEG) LY30 suggestive SD. We therefore hypothesized that two distinct phenotypes of SD exist, one, which is driven by t-PA inhibition, whereas another is due to an inadequate t-PA release in response to injury.
C
ritically injured patients require a delicate balance of clot formation and degradation (fibrinolysis) to prevent excessive bleeding from injured sites while keeping the microcirculation patent. It has been recognized for decades that coagulation is never intended to reach a physiologic [PY] endpoint; 1 that is, clot formation and degradation are always occurring to prevent bleeding but keep the vasculature patent. In trauma, the extreme ends of the fibrinolytic system (hyperfibrinolysis [HY] and fibrinolysis shutdown [SD] ) have been identified as predictors of mortality. 2 Fibrinolysis SD has been documented in a large population of severely injured adult trauma patients 3 and recently has recently been identified as a pathologic coagulation change in pediatric trauma patients. 4 Fibrinolysis SD is not a new concept and was identified as the driver of irreversible shock after hemorrhage by Hardaway in 1963. 5 Despite the known existence of fibrinolysis SD for over half a century, the mechanisms driving this process remain poorly defined.
The development of postoperative fibrinolysis resistance has been described in other surgical specialties and attributed to a dramatic increase in plasminogen activator inhibitor-1 (PAI-1) several hours after completion of an operation. 6, 7 However, the role of elevated PAI-1 driving fibrinolysis SD acutely after injury remains to be defined. The largest source of PAI-1 that can be immediately released into circulation is from platelets. 8 A previous analysis using a modified TEG to quantify sensitivity to tissue plasminogen activator (t-PA) identified an inverse correlation between platelet function and sensitivity to fibrinobrinolysis. 9 Therefore, platelet activation may result in early increased levels of PAI-1 acutely after injury and result in fibrinolysis SD.
Alternative explanations for postinjury fibrinolysis resistance also exist. Although high levels of t-PA have been ascribed to the hyperfibrinolytic phenotype, 10, 11 the converse may also be true for fibrinolysis SD; that is, these patients have low t-PA activity from impaired t-PA generation after injury. This could represent a component of the endotheliopathy of trauma. In a previous animal study, the development of acute fibrinolysis resistance was associated with low systemic t-PA levels without an increase in PAI-1. 12 The rapid TEG (r-TEG) cutoffs for fibrinolysis SD 2 cannot distinguish a t-PA-resistant versus inadequate t-PA production mechanism of fibrinolysis SD. Therefore, we hypothesized that two distinct phenotypes of SD exist, one, which is driven by t-PA inhibition, whereas another is due to an inadequate t-PA release in response to injury.
METHODS

Patient Population
Prospective observation study of adult trauma patients meeting criteria for the highest level of activation at our Level I trauma center (Denver Health Medical Center/University of Colorado) from 2014 to 2016 that had blood samples obtained within an hour of injury. Trauma criteria activation includes; hypotension (SBP < 70 or SBP < 90 and HR > 108), airway compromise, gunshot wound to neck, chest or abdomen, Glasgow Coma Scale score less than 8 secondary to trauma mechanism, blood product transfusion requirement. All patients had samples collected under protocols approved by the Colorado Multiple Institutional Review Board for prospective evaluation of coagulation in response to trauma. Patient demographics, injury mechanism, laboratory results, and transfusion requirements were recorded by professional research assistants (PRA) who provide onsite, continuous coverage of the emergency department (ED).
Blood Collection
Blood was collected in 3.5-mL tubes containing 3.2% citrate in the prehospital ambulance or upon arrival to the ED. Prehospital or ED healthcare workers drew study patient blood samples concurrently with the first set of blood samples used for in-hospital laboratory analysis. PRAs performed TEG assays within 2 hours of blood draw.
Outcomes
PRA collected all clinical and demographic data on patients from the time they arrived to the ED until discharge or death. The patients presenting clinical coagulopathy score was determined by the attending trauma surgeon in the ED. This methodology was the score has been previously published. 13 Blood transfusion requirements were recorded over the first 24 hours. A massive transfusion was considered as 10 or more units of red blood cells within the first 6 hours of injury. Mortality was determined during hospitalization.
Thrombelastography Assays
Viscoelastic assays were completed by a team of trained PRA with extensive experience in multiple types of TEG assays. Citrated blood samples were analyzed using the TEG 5000 Thrombelastography Hemostasis Analyzer (Haemonetics, Niles, IL). The following indices were obtained from the tracings of the TEG: reaction time (R-time min.), angle (°), maximum amplitude (MA [mm]), and lysis 30 minutes after MA (LY30 [%]). Modified assays to quantify sensitivity to fibrinolysis were run in parallel with rapid TEG assay (r-TEG, activated by tissue factor and kaolin). The same TEG analyzer was used for this assay without an activator (native TEG), but before recalcification exogenous t-PA (t-TEG) was added. This t-PA challenge of whole blood has been previously validated to quantify t-PA sensitivity and resistance in vitro to assess the effects of different proteins, 14, 15 as well as clinically in trauma patients. 9 In brief, 500 μL of whole blood were pipetted into a customized vial containing lyophilized t-PA (Molecular Innovation, Novi, MI) to a final concentration of 75 ng/mL of t-PA, and mixed by gentle inversion. A 340-μL aliquot of this mixture was then transferred to a 37°C TEG cup, preloaded with 20 μL of 0.2 mol/L CaCl 2 .
Platelet Mapping
Whole blood collected in heparin (19 U·mL ) was analyzed with the TEG/platelet mapping assay (Haemonetics) and was mixed with a solution containing reptilase and FXIIIa and then activated with 2 millimolar ADP. The same research assistants who ran TEGs also ran all platelet mapping assays. The maximum clot strength (ADP MA) was used to quantify platelet function.
Fibrinolysis Phenotyping
Patients were stratified into two groups based on the t-TEG LY30. To our knowledge, no preexisting threshold of t-PA hypersensitivity (HS) using TEG has previously been defined. Using the data collected on a population of 160 healthy volunteers using the same t-TEG as describe in Materials and methods section, we assumed, based on the distribution of LY30, that a value greater than 95th percentile would not be normal. Our defined threshold for t-PA HS was a t-TEG LY30 greater than 27% (95th percentile of 160 healthy volunteers), and those patient with a lower t-TEG LY30 were classified as non-hypersensitive (nHS). Within these two cohorts, an additional stratification was performed to divide patients into three fibrinolysis phenotypes based on their r-TEG as reported previously. 3 The thresholds for each phenotype were SD LY30, less than 0.9%; PY, 0.9% to 2.9%; and HY, greater than 2.9%. This resulted in a total of six unique fibrinolysis phenotypes.
Nested Patient Population
Within each phenotype, 18 patients (total 108) were selected based on the highest Injury Severity Score (NISS) per group to represent comparable injury severity between phenotypes. This was conducted to eliminate the inclusion of nonseverely injured trauma patients for protein analysis and reduce the probability of confounding proteomic changes attributable to a generic response to severe injury.
t-PA and PAI-1 Activity and Concentration PAI-1 and t-PA activity, in addition to quantification of their inactive PAI-1/t-PA complex, were measured via ELISA (Molecular Innovations, Novi, MI). Samples were run in duplicate on previously frozen plasma blood samples which were matched to whole-blood TEG analysis. Activity levels were quantified by IU per ml and complex levels were represented as ng/mL.
Targeted Proteomic Analysis
A targeted proteomic approach with 13 C stable isotopelabeled internal standards (heavy standards) was used to identify the relative concentrations of regulators and substrates of the fibrinolytic system. Proteins were selected based on their participation or regulation of coagulation and fibrinolysis (shown in Table 3 ). These include regulators of PAI-1 activity and degradation (vitronectin, protein C, proteins S), back up inhibitors of t-PA and plasmin (alpha 1-antitrypsin, alpha 2-antiplasmin [α2-AP], alpha-2-macroglobulin [α2M], C-1 esterase inhibitor) fibrin clot modifying proteins (factor XIII, Von Willebrand Factor, thrombin activatable fibrinolysis inhibitor [TAFI]), alternative plasminogen activator (urokinase [u-PA]), in addition to tissue factor, plasminogen, and fibrinogen. Proteomic analysis was performed on plasma samples in trauma patients in a similar fashion as described previously 15 without protein depletion. In brief, samples were mixed in a 10-kDa cutoff filter unit with 8 M urea in 0.1 M ABC (pH 8.5) and centrifuged. Proteins were reduced by addition of 100 μL of 10 mM dithiothreitol in 8 M urea and 0.1 M ABC (pH 8.5) and incubation for 30 minutes at room temperature. Subsequently, 100 μL of 55 mM iodoacetamide in 8 M urea in 0.1 M ABC (pH 8.5) was added to the samples, and the samples were incubated for 30 minutes at room temperature followed by centrifugation. Protein digestion was carried out with the presence 0.02% of surfactant trypsin enhancer (ProteaseMax; Promega, Madison, WI) surfactant at 37°C overnight. Peptides were recovered by transferring the filter unit to a new collection tube and centrifuged. Samples were then concentrated to approximately 2 μL and reconstituted to 50 μL with 0.1% formic acid. The resultant peptide mixture was analyzed by LC single-reaction monitoring (SRM). Targeted SRM approach was performed using an LC-MS/MS system interfaced with a UPLC system (QTRAP 5500 and Ultimate 3000, respectively; Thermo Fisher Scientific, San Jose, CA). Five micrograms of proteins was separated on an UPLC BEH C18 1.7 μm 1.0 Â 150-mm column (ACQUITY; Waters, Milford, MA) kept at constant 50°C. The mobile phases consisted of 0.1% formic acid in double-distilled (18 mΩ) water (A) and 0.1% formic acid in 80% acetonitrile with (B), respectively. Samples were eluted at a flow rate of 150 μL/min using a gradient of 5% to 32% B for 32 minutes followed by a wash step of 5 minutes at 100% B ending with a reequilibration step of 7 minutes at 5%. The mass spectrometer was run in positive ionization mode with the following settings: a source temperature of 200°C
, spray voltage of 5300 V, curtain gas of 20 psi, and a source gas of 35 psi (nitrogen gas). Multiple SRM transitions were monitored using unit resolution in both Q1 and Q3 quadrupoles to maximize specificity. SRM assay optimization was performed with the aid of computer software (Skyline, Version 3.1; UW, Seattle, WA). Collision energies and declustering potential were optimized for each transition. Method building and acquisition were performed using the instrument-supplied software (Analyst, Version 1.5.2; AB Sciex, Framingham, MA). Raw SRM data files were imported to Skyline Version 3.1 software for data processing. Transition quality, peak shape, and peak area boundaries were manually validated. Integrated peak areas were calculated by the software after Savitsky-Golay smoothing, and quantification was based on the ratio of the 12 C peptide representing the endogenous sample to the corresponding 13 C peptide.
Statistical Analysis
SPSS version 23 (IBM, Armonk, NY) was used for statistical analysis. TEG measurements are presented as median and interquartile values. T-PA-sensitive versus nonsensitive cohorts were contrasted with Mann-Whitney U test for continuous variables and χ 2 for dichotomous variables. Multivariate logistic regression analysis was performed with t-PA sensitivity as the dependent variable, with all significant variables from dichotomous comparisons in a backward stepwise model to eliminate nonsignificant variables after adjustment. Overall model significance was determined by area under the curve of a receiver operator characteristic curve. Fibrinolysis phenotypes characteristics were contrasted with a Kruskal-Wallis test for continuous variables or χ 2 for categorical. Correlations between t-PA and PAI-1 activity levels were correlated with Spearman rho to TEG and clinical variables. Proteomics were normalized to the overall median value of the specific protein analyzed. The values represent the groups' median percent change to overall populations median value. Conditional formatting using Excel version 15.23 (Microsoft, Redmond, WA) was used to visually quantify differences between groups medians and proteins. Red represents the 95th percentile of difference in protein levels changes, whereas blue represents the 5th percentile of protein differences (decrease), and white is representative of the 50th percentile (median). Statistical analysis of individual proteins was conducted with a Kruskal-Wallis test for overall significance between groups and within each sensitivity cohort with an alpha set to 0.015 for multiple comparisons and 0.05 considered as a trend.
RESULTS
Patient Population
Three hundred ninety-eight patients were included in the study. Patients were predominantly men (80%) and with a median age of 33 years (interquartile range [IQR], 26-48 years). The median NISS was 18 (IQR, 6-34) with 46% of patients sustaining penetrating wounds, with a median admission lactate of 3.9 (IQR, 2.7-6.0), and a mortality rate of 13%. The nested cohort of 108 patients with proteomic and ELISA analyses, were predominantly men (71%) with a median age of 33 years (IQR, 28-49 years), and the median NISS was 41 (IQR, 31-50) with 31% of patient sustaining penetrating wounds, and a mortality rate of 24%.
Classification by t-PA HS
Tissue plasminogen activator sensitivity defined by t-TEG LY30 was present in 27% of the patients (n = 109). Patient demographic, injury patterns, and initial laboratory values, and coagulation assessment of patients with and without t-PA sensitivity are displayed in Table 1 . After conducting a backward step regression analysis of significant differences between cohorts NISS (p < 0.001), INR (p = 0.006), platelet count (p = 0.033), and ADP platelet function (p = 0.001) remained significant predictors of t-PA sensitivity (model receiver operator characteristic curve, 0.852; p < 0.001). There was no significant difference in the distribution between fibrinolysis phenotypes within the t-PA HS and nHS cohorts (HY, 32% vs 23%; PY, 45% vs 55%; SD, 23% vs 22%; p = 0.183 Fig. 1) . Patients who were t-PA HS had a higher rate of MT (26% vs 3%; p < 0.001) and increased mortality (33% vs 5%; p < 0.001).
Stratification by Fibrinolysis Phenotypes
In the overall patient population, the majority of patients had a normal clinical coagulopathy score, but when stratified by fibrinolysis phenotype (not taking into account t-PA HS), HY was associated with a higher frequency of clinicianappreciated coagulopathy (median, 1; IQR, 1-3 vs SD, 1; IQR, 1-2 vs PY, 1; IQR, 1-2; p = 0.008). Hyperfibrinolysis was also associated with the highest rate of massive transfusion (18% vs SD, 10% vs PY, 5%; p < 0.001) and mortality was increased in patients with HY and SD compared with a PY coagulation phenotype (p = 0.020 Fig. 2 ).
Six Phenotypes
Differences between coagulation parameters, coagulopathy score, and massive transfusion rates within the six patient cohorts are listed in Table 2 . Within stratum (t-PA HS and nHS), overall differences between phenotypes and clinical coagulopathy scores trended to be higher in both SD and hyper ( Table 2 ). The MT rate within stratum remained significantly different between phenotypes with HY having the highest rate (47%; p = 0.002) in the t-PA HS group, whereas SD had the highest rate of massive transfusion (8%; p = 0.009) in the nHS group. Injury patterns differed in the six phenotypes (Table 3 ). In general, t-PA HS patients had higher Abbreviated Injury Severity and overall NISS to nHS patients. However, a clear injury pattern or mechanism did not emerge in the individual phenotypes within t-PA-versus non-t-PA-sensitive cohorts. Mortality was also significantly different in the nHS-sensitive group (p = 0.001 Fig. 2 ). In this cohort, fibrinolysis SD had a mortality rate of 14%, which was higher than PY (3% p = 0.003) and SD (1.5% p = 0.006). When stratified by t-PA HS, HY had a mortality rate of 45%, which was higher than PY (25% p = 0.049) and SD (32% p = 0.304) although not significant overall (p = 0.139). In the cohort undergoing proteomic analysis, there was no overall difference in NISS (p = 0.112) and injury pattern (p = 0.336), but differences existed between rates of massive transfusion (p = 0.017) and mortality (p = 0.015), which had the same pattern as the overall patient population.
t-PA and PAI-1 Activity Levels
PAI-1 activity and complex levels were available on all 108 patients, 78 patients had t-PA activity levels measured due technical difficulties with assay and limited plasma availability. t-PA activity correlated to r-TEG LY30 (Rho 0.383 p < 0.001) and T-TEG LY30 (Rho 0.470 p < 0.001) and improved when combining variable (T-TEG*r-TEG LY30 Rho =0.537 p < 0.001), but did not correlation with platelet function (rho, −0.003; p = 0.985). PAI-1 activity demonstrated a similar trend with r-TEG LY30 (rho, −0.286; p = 0.002) and T-TEG (rho, −0.514; p < 0.001) but did not improve with combining terms (rho, −0.508; p < 0.001) and did not correlate with platelet function (rho, 0.44; p = 0.685). Overall t-PA activity (p = 0.002), PAI-1 (p < 0.001), and t-PA/PAI-1 complex levels (p = 0.006) differed between the six phenotypes (Fig. 3) . In the t-PA HS group, all three comparisons were also significantly different (t-PA, p = 0.003; PAI-1, p = 0.009; and complex, p = 0.044). Only the complex levels differed between phenotypes in the nonsensitive group (p = 0.037). The SD cohort that were nHS had a median 12-fold reduction in t-PA activity (p < 0.001) and 21 times more PAI-1 activity (p = <0.001) compared with t-PA-HS cohort.
Proteomic Analysis
The median percent changes in coagulation proteins compared with the populations' overall median levels are displayed in Table 4 , and individual relative protein levels are displayed in supplemental Figure 1 . Of the 19 proteins analyzed, 10 (52%) were significantly different overall between the six cohorts. Within the t-PA HS group, 5 proteins (26%) remained significant (Table 4) , and in the SD group, no significant differences existed between groups, but there was a trend toward lower u-PA levels in the SD group (p = 0.029), with trends toward elevated levels of vitronectin (p = 0.027) and coagulation factor XIII (p = 0.043 Table 4 ) for both SD and HY in the nHS cohort.
DISCUSSION
Fibrinolysis phenotypes based on decreased clot strength at 30 minutes from a standard viscoelastic assay (rapid TEG LY30) demonstrate increased mortality at the pathologic extremes of fibrinolysis. Additional stratification of these patients based on sensitivity to t-PA-mediated fibrinolysis, however, demonstrates that unique subphenotypes exist within the originally described spectrum of fibrinolysis. t-PA sensitivity is associated with a number of clinical indices of shock, increased injury severity, and platelet dysfunction. Within this cohort of t-PA HS patients, those with HY had the highest mortality rate, followed by fibrinolysis SD. However, in the nHS group, fibrinolysis SD was associated with a fivefold mortality compared with PY and hyperfibrinolytic patients. The association of pathologic fibrinolysis phenotype and mortality after trauma has been reported previously in both adult 2, 3 and pediatric 4 patients. Although increases in t-PA activity and depletion of PAI-1 have been implicated in HY, 10,11 the mechanisms driving acute fibrinolysis SD remain unclear. A previous hypothesis was that acute fibrinolysis SD is driven by increased inhibitors of fibrinolysis;
2 however, the current study has shown that patients can be in a state of fibrinolysis SD without upregulation of PAI-1 or α2-AP, and unexpectedly can be hypersensitive to t-PA-mediated fibrinolysis. The interaction between systemic fibrinolytic activity (measured by rapid TEG LY30) and t-PA sensitivity (measured by t-PATEG LY30) is significant. Therefore, it is important consider these findings when resuscitating patients, because the distribution of phenotypes within nHS and t-PA HS patients is similar.
Platelets and Plasma Regulation of Fibrinolysis
Platelet alpha-granule contain potent inhibitors of fibrinolysis 15 and sensitivity to t-PA has previously been associated with platelet dysfunction in trauma patients. 9 Early descriptions of platelet dysfunction using a viscoelastic assay to measure platelet function suggests that inhibition of the ADP pathway was associated with increased mortality and administration of blood products. 16 Recently, it has been demonstrated that dysfunction of the ADP pathway in trauma patients is associated with an impaired ability to release platelet granules 17 rather than platelet exhaust (release of all contents resulting in circulating platelets with no granules), which is seen in other clinical scenarios. 18 Although platelets may be a component of fibrinolysis regulation, plasma is a buffer of t-PA-mediated fibrinolysis. 19 This study demonstrates that a number of proteins become depleted in patients who are t-PA HS and hyperfibrinolytic. Not only is PAI-1 activity decreased, but also t-PA's backup inhibitor C1 esterase 20 are also relatively depleted, along with additional downstream regulators of fibrinolysis including TAFI, 21 factor-XIII, 22 and α2-AP. 23 These results suggest that platelets and plasma proteins both regulate fibrinolysis to a degree, but the manifestation of overt HY is dependent on failure of both systems. This is further supported by only the t-PA HS hyperfibrinolytic patients having significant decrease in fibrinogen and plasminogen. Decreases in both of these proteins is indicative that plasmin has been generated and fibrin/fibrinogen has been depleted supporting overt systemic HY. The t-PA HS SD patients also have a high rate of mortality and demonstrate depletion of fibrinolytic regulators, but have decreased clot degradation as measured by rapid TEG. A similar phenotype has been described previously in patients analyzed with ROTEM, in which high plasmin antiplasmin levels and low fibrinolytic activity were associated with poor outcomes. 24 These data suggest that even after PAI-1 is depleted, the additional regulators of fibrinolysis can prevent systemic fibrinolysis. The differences in protein levels between the t-PA HS groups suggest mechanistic differences. The higher levels of Von Willebrand factor in hyperfibrinolytic patients suggests that t-PA is released from an endothelial source, because prestored t-PA is known to colocalized in endothelial Weibel-Palade bodies. 25 Several fibrinolytic inhibitors are decreased in both the SD and hyperfibrinolytic groups. However, complex t-PA and PAI-1 levels are increased in the SD group. These SD t-PA HS patients have potentially experienced fibrinolysis, but at the time of blood draw had low systemic fibrinolysis activity, which could be the adaptive response to activating the fibrinolytic system.
SD Because of Inadequate Plasminogen Activators?
In the t-PA nonsensitive cohort, there were no significant increases in fibrinolytic regulators between the SD and HY. Shutdown patients on the other hand, may be deficient in a profibrinolytic mechanism to promote a PY state of fibrinolysis that extends beyond t-PA. Animal work has supported that a deficiency of u-PA and upregulation of PAI-1 after lung injury leads to increased lung damage and pulmonary fibrinosis. 26 Urokinase levels were relatively low in both of the SD phenotypes (t-PA HS and nHS). Interestingly, the highest PAI-1 activity levels were in the hyperfibrinolytic non-t-PA HS group, who also had the highest u-PA levels but the lowest overall mortality. Future investigation into the temporal changes of u-PA after injury may provide mechanistic insight into a potential protective mechanism from fibrinolysis SD with this alternative plasminogen activator.
Emerging data suggest that a second wave of fibrinolysis SD after trauma is common and is associated with a large increase in PAI-1 levels several hours of resuscitation. 27 This reperfusion SD at 4 hours from injury is associated with PAI-1 levels that are 20-fold higher than the median level of patients in the SD non-t-PA HS cohort from this study. Patients that are in a persistent fibrinolysis SD state have nearly a fourfold increase in mortality compared with patients who normalize their fibrinolytic activity measured by TEG. 28 From these data, it is unlikely that PAI-1 is the sole driver of acute fibrinolysis SD, and additional modifiers, such as uPA, may play a role in preventing prolonged fibrinolysis resistance.
Clinical Applicability
The clinical relevance of these data is that the patients that are t-PA HS need to buffer their fibrinolytic system, but the majority do not require direct fibrinolysis inhibition. These patients tend to be more severely injured and have higher rates of massive transfusion with overall laboratory coagulation scores suggestive of coagulopathy, except for fibrinolysis (LY30, Table 1 ). The benefit from an antifibrinolytic is likely only limited to those patients within this cohort with an elevated LY30. This may explain why the previous report of using an LY30 of 3% cutoff for administering TXA has not been associated with improved mortality. 29 However, using a t-PA TEG is not clinically feasible at this time because it is not Food and Drug Administration-approved. INR may serve as a surrogate for t-PA sensitivity for the time being, as it has recently been identified that an elevated INR early after injury is due to fibrinogen depletion, presumed from HY. 30 Our study also identified low fibrinogen, elevated INR, and protein C depletion in t-PA HS hyperfibrinolytic patients, yet INR can also be elevated in SD t-PA HS patients, so should not be used as a sole indicator for TXA administration.
Early fibrinolysis SD may represent a biomarker of poor outcomes, or unmeasured modifiers of fibrinolysis may be acting to inhibit fibrinolytic activity. Although early SD may not be preventable, reperfusion SD leading to persistent fibrinolysis SD 28 can potentially be attenuated by minimizing platelet transfusions in these patients. Platelet transfusions and TXA were both associated with reperfusion fibrinolysis SD that persists beyond 12 hours. 27 Using a goal-directed approach to selectively administer platelets in these patients is a rational approach. Prospective data have demonstrated that empiric high ratios of platelets are associated with no overall improvement in 30-day survival. 31 Point of care TEG-based resuscitation has prospectively been shown to decreased early platelet transfusions in trauma patients undergoing a massive transfusion and reduce mortality by 50%. 32 Although this was an unexpected finding from this randomized control trial, data from this study begin to suggest a mechanism for overutilization of platelets in fibrinolysis SD leading to increased morbidity and mortality. The dangers of liberal platelet transfusions was recently demonstrated in a randomized control trial to treat hemorrhagic stroke patients taking antiplatelet medication, in which empiric platelet transfusion were associated with increased mortality. 33 This article was limited to defining patients that were hypersensitive versus non-hypersensitive to t-PA mediated fibrinolysis. In this study, we do not address t-PA-resistant (t-TEG LY30 < 5th percentile healthy volunteers) patients. This would create nine phenotypes of fibrinolysis and a loss of statistical power to differentiate outcomes. However, preliminary analysis of patients that are t-PA-resistant demonstrates that SD has the highest morality rate in this cohort, and that HY defined by rapid TEG also exists in this cohort. Another limitation of this study is that we measured relative protein concentrations between phenotypes using mass spectrometry, and not the activity level of proteases beyond t-PA and PAI-1. Some of these proteins evaluated in the study which were different between phenotypes, but were not statically significant (like TAFI), were due to high variability between patients. There is still a large gap in knowledge in understanding fibrinolysis changes after injury, and it is becoming increasingly apparent that this process is not regulated solely by protein C, as previously hypothesized. 34 In conclusion, acute fibrinolysis SD is not caused by a single etiology. The differential phenotypes require an ongoing investigation to identify the optimal resuscitation strategy for these patients. Equally as important, not all hyperfibrinolytic trauma patients have pathologic coagulation changes. Only those patients with t-PA sensitivity have confirmation of a dysregulated fibrinolytic system with a pan coagulopathy. We no longer consider an LY30 greater than 3% an indication for anti-fibrinolytics and have adopted an LY30 greater than 5% as our current threshold, while taking into consideration the implementation of an INR > 1.5 + LY30 > 5% for a more definitive indication.
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